Stromal-Based Signatures for the Classification of Gastric Cancer [RRT2]

ABSTRACT: Increasing success is being achieved in the treatment of malignancies with stromal-targeted therapies, predominantly in anti-angiogenesis and immunotherapy, predominantly checkpoint inhibitors. Despite 15 years of clinical trials with anti-VEGF pathway inhibitors for cancer, we still find ourselves lacking reliable predictive biomarkers to select patients for anti-angiogenesis therapy. For the more recent immunotherapy agents, there are many approaches for patient selection under investigation. Notably, the predictive power of an Ad-VEGF-A164 mouse model to drive a stromal response with similarities to a wound healing response shows relevance for human cancer and was used to generate stromal signatures. We have developed gene signatures for 3 stromal states and leveraged the data from mul

ORGANISM(S): Mus musculus

SUBMITTER: Jiangang Liu 

PROVIDER: E-GEOD-76628 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress